Settlement reached, allowing generic versions of Ingrezza in 2038

  • Neurocrine Biosciences settles patent litigation related to Ingrezza drug applications
  • Four companies will have the right to sell generic versions of Ingrezza starting in March 2038
  • Settlement reinforces belief in the strength of Ingrezza intellectual property estate

Neurocrine Biosciences has successfully resolved all patent litigation surrounding the new drug applications for its tardive dyskinesia treatment, Ingrezza. As part of the settlement, four companies will now have the right to sell generic versions of Ingrezza starting in March 2038, or earlier under certain circumstances. This settlement not only provides clarity regarding Ingrezza exclusivity but also reinforces the company’s confidence in the strength of its intellectual property estate.

Public Companies: Neurocrine Biosciences (Unknown)
Private Companies:
Key People: Darin Lippoldt (Chief Legal Officer)

Factuality Level: 8
Justification: The article provides factual information about Neurocrine Biosciences resolving patent litigation related to its drug Ingrezza. It includes a quote from the Chief Legal Officer of the company, which adds credibility to the information provided.

Noise Level: 7
Justification: The article provides some relevant information about Neurocrine Biosciences resolving patent litigation related to its tardive dyskinesia treatment Ingrezza. However, it lacks in-depth analysis, scientific rigor, and evidence to support its claims. It also does not provide any actionable insights or solutions. The article stays on topic but is quite short and does not provide much detail.

Financial Relevance: Yes
Financial Markets Impacted: Neurocrine Biosciences

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article pertains to a financial company, Neurocrine Biosciences, resolving patent litigation related to its drug Ingrezza. There is no mention of an extreme event or its impact rating.

Reported publicly: www.marketwatch.com